BR0108865A - Métodos de tratamento do câncer e da dor a ele associada usando antagonistas de endotelina - Google Patents

Métodos de tratamento do câncer e da dor a ele associada usando antagonistas de endotelina

Info

Publication number
BR0108865A
BR0108865A BR0108865-3A BR0108865A BR0108865A BR 0108865 A BR0108865 A BR 0108865A BR 0108865 A BR0108865 A BR 0108865A BR 0108865 A BR0108865 A BR 0108865A
Authority
BR
Brazil
Prior art keywords
methods
treating cancer
associated pain
endothelin antagonists
preventing
Prior art date
Application number
BR0108865-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Todd J Janus
Robert J Padley
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR0108865A publication Critical patent/BR0108865A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0108865-3A 2000-08-07 2001-08-06 Métodos de tratamento do câncer e da dor a ele associada usando antagonistas de endotelina BR0108865A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63338900A 2000-08-07 2000-08-07
PCT/US2001/024716 WO2002011713A2 (en) 2000-08-07 2001-08-06 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists

Publications (1)

Publication Number Publication Date
BR0108865A true BR0108865A (pt) 2005-04-19

Family

ID=24539436

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108865-3A BR0108865A (pt) 2000-08-07 2001-08-06 Métodos de tratamento do câncer e da dor a ele associada usando antagonistas de endotelina

Country Status (22)

Country Link
EP (1) EP1347751B1 (https=)
JP (3) JP4217068B2 (https=)
KR (1) KR20030027007A (https=)
CN (1) CN1635878A (https=)
AR (1) AR031122A1 (https=)
AT (1) ATE465728T1 (https=)
AU (2) AU8113401A (https=)
BG (1) BG107577A (https=)
BR (1) BR0108865A (https=)
CA (1) CA2416879C (https=)
DE (1) DE60141979D1 (https=)
HU (1) HUP0302977A2 (https=)
IL (1) IL153769A0 (https=)
MX (1) MXPA03000984A (https=)
NO (1) NO20030593D0 (https=)
NZ (1) NZ523562A (https=)
PE (1) PE20020273A1 (https=)
PL (1) PL366160A1 (https=)
SK (1) SK1782003A3 (https=)
TW (1) TWI306760B (https=)
WO (1) WO2002011713A2 (https=)
ZA (1) ZA200300253B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
JP5070051B2 (ja) * 2004-06-07 2012-11-07 クー バイオロジックス インク. 癌を治療するための細菌組成物
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
NZ702796A (en) 2010-07-26 2017-03-31 Qu Biologics Inc Immunogenic anti-inflammatory compositions
CN102485238A (zh) * 2010-12-06 2012-06-06 陈炯华 芎芷镇痛方
JP6632607B2 (ja) 2014-05-02 2020-01-22 クー バイオロジックス インク.Qu Biologics Inc. 抗微生物免疫修飾

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
ES2259803T3 (es) * 1996-02-13 2006-10-16 Abbott Laboratories Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina.
NZ502395A (en) 1997-08-04 2002-08-28 Abbott Lab 4-Benzodioxolyl substituted pyrrolidine-3-carboxylic acid derivatives useful as endothelin antagonists
AU4382499A (en) * 1998-12-11 2000-07-03 Mactapes Limited Curtain heading tape manufacture
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity

Also Published As

Publication number Publication date
PE20020273A1 (es) 2002-04-16
CA2416879A1 (en) 2002-02-14
CN1635878A (zh) 2005-07-06
ZA200300253B (en) 2004-11-17
JP4217068B2 (ja) 2009-01-28
HUP0302977A2 (hu) 2003-12-29
WO2002011713A2 (en) 2002-02-14
NZ523562A (en) 2006-10-27
IL153769A0 (en) 2003-07-06
JP2004520266A (ja) 2004-07-08
MXPA03000984A (es) 2003-09-05
NO20030593L (no) 2003-02-06
ATE465728T1 (de) 2010-05-15
DE60141979D1 (de) 2010-06-10
BG107577A (bg) 2003-10-31
JP2007084564A (ja) 2007-04-05
NO20030593D0 (no) 2003-02-06
TWI306760B (en) 2009-03-01
PL366160A1 (en) 2005-01-24
WO2002011713A3 (en) 2003-07-17
AU8113401A (en) 2002-02-18
AR031122A1 (es) 2003-09-10
JP2007063288A (ja) 2007-03-15
AU2001281134B2 (en) 2005-06-09
CA2416879C (en) 2006-11-07
SK1782003A3 (en) 2003-08-05
EP1347751A2 (en) 2003-10-01
EP1347751B1 (en) 2010-04-28
KR20030027007A (ko) 2003-04-03

Similar Documents

Publication Publication Date Title
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
IL182908A0 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
CY1108201T1 (el) Συσκευες διαδερματικης απελευθερωσης οπιοειδους που ειναι ανθεκτικες στην παραβιαση
MXPA05006670A (es) Administracion de capsaicinoides.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DK0998287T3 (da) Anvendelse af levobupivacain
DE602004005814D1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
NO20004419D0 (no) Ny anvendelse
BR0108865A (pt) Métodos de tratamento do câncer e da dor a ele associada usando antagonistas de endotelina
PT981347E (pt) Utilizacao de levobupivacaina em cirurgia facial
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
ID23799A (id) Penggunaan antagonis reseptor 5ht2 spesifik untuk pembuatan obat obatan yang berguna dalam pengobatan sindrom apnea saat tidur
BR0315140A (pt) Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação
DE60204694D1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
PT1255538E (pt) Utilizacao do acido 2-metil-tiazolidin-2,4-dicarboxilico e/ou sais compativeis fisiologicamente para tratamento e/ou prevencao de cancros
BR9908190A (pt) Processos para tratar a dor especìfica de fêmea em um paciente fêmea, e para tratar a dor crÈnica em um paciente
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
BR0113646A (pt) Tratamento de distúrbios inflamatórios
DK1251850T3 (da) Anvendelse af et kombinationspræparat i cancerbehandling
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
TR200100670T2 (tr) R(+)-alfa-(2,3-Dimetoksifenil)-1- [2-(4-florofenil)etil]-4-piperidinmetanol' ün uyku düzensizlikleri tedavisinde kullanımı.
BRPI0407574A (pt) combinações farmacêuticas que compreendem um inibidor de nos e um antagonista de receptor de nmda

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S)8O, 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.